MedTrace Logo

A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

NCT03542994 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2021-11-09

No results posted yet for this study

Summary

Evelo will investigate the safety and tolerability of EDP1066 and its potential to be a medicinal product in healthy volunteers and individuals with mild to moderate psoriasis and atopic dermatitis.

Conditions

Interventions

OTHER

EDP1066

EDP1066 is an orally administered monoclonal microbial

DRUG

Placebo oral capsule

placebo

Sponsors & Collaborators

  • Evelo Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Duncan McHale, MD, PhD · Evelo Biosciences

  • Daryl Bendel, MBChB, MBA · University of Surrey

  • Giuseppe Fiore, MD · Medicines Evaluation Unit Ltd

  • Aliya Asher, MD · MAC Clinical Research

  • Richard Fitzgerald, MD · Royal Liverpool Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-24
Primary Completion
2020-01-03
Completion
2020-01-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542994 on ClinicalTrials.gov